Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol

Summary

Randomized study. Patients with coronary artery disease equivalent will be randomized to receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day. Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment. Hypothesis is that ezetimibe will lower oxidized LDL

Timeline

Start

2008-09

Primary completion

2009-06

Completion

2009-06

Drugs

Indications